Annual EBITDA
-$24.32 M
+$704.00 K+2.81%
31 December 2023
Summary:
Enlivex Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$24.32 million, with the most recent change of +$704.00 thousand (+2.81%) on 31 December 2023. During the last 3 years, it has fallen by -$14.82 million (-155.98%). ENLV annual EBITDA is now -10518.34% below its all-time high of -$229.00 thousand, reached on 31 December 2012.ENLV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.83 M
+$936.00 K+24.88%
30 June 2024
Summary:
Enlivex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.83 million, with the most recent change of +$936.00 thousand (+24.88%) on 30 June 2024. Over the past year, it has increased by +$2.59 million (+47.80%). ENLV quarterly EBITDA is now -187.85% below its all-time high of $3.22 million, reached on 31 December 2017.ENLV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$17.89 M
+$3.61 M+16.79%
30 June 2024
Summary:
Enlivex Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$17.89 million, with the most recent change of +$3.61 million (+16.79%) on 30 June 2024. Over the past year, it has increased by +$8.16 million (+31.31%). ENLV TTM EBITDA is now -2811.06% below its all-time high of $660.00 thousand, reached on 30 September 2018.ENLV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.8% | +47.8% | +31.3% |
| 3 y3 years | -156.0% | +23.8% | -21.9% |
| 5 y5 years | -369.6% | -41.3% | -121.6% |
ENLV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -156.0% | +2.8% | at high | +63.1% | -21.9% | +31.5% |
| 5 y | 5 years | -369.6% | +2.8% | -53.4% | +63.1% | -123.9% | +31.5% |
| alltime | all time | <-9999.0% | +2.8% | -187.8% | +63.1% | -2811.1% | +31.5% |
Enlivex Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$2.83 M(-24.9%) | -$17.89 M(-16.8%) |
| Mar 2024 | - | -$3.76 M(-36.1%) | -$21.50 M(-11.6%) |
| Dec 2023 | -$24.32 M(-2.8%) | -$5.89 M(+8.8%) | -$24.32 M(-6.7%) |
| Sept 2023 | - | -$5.41 M(-15.9%) | -$26.05 M(-0.3%) |
| June 2023 | - | -$6.44 M(-2.1%) | -$26.12 M(+2.9%) |
| Mar 2023 | - | -$6.57 M(-13.8%) | -$25.38 M(+1.4%) |
| Dec 2022 | -$25.02 M(+33.5%) | -$7.62 M(+39.0%) | -$25.02 M(-0.2%) |
| Sept 2022 | - | -$5.49 M(-3.7%) | -$25.06 M(+7.6%) |
| June 2022 | - | -$5.70 M(-8.4%) | -$23.28 M(+9.4%) |
| Mar 2022 | - | -$6.22 M(-18.9%) | -$21.27 M(+13.5%) |
| Dec 2021 | -$18.74 M(+97.3%) | -$7.66 M(+106.7%) | -$18.74 M(+27.7%) |
| Sept 2021 | - | -$3.71 M(+0.6%) | -$14.68 M(+14.2%) |
| June 2021 | - | -$3.69 M(+0.0%) | -$12.86 M(+13.3%) |
| Mar 2021 | - | -$3.69 M(+2.4%) | -$11.34 M(+19.4%) |
| Dec 2020 | -$9.50 M(+12.9%) | -$3.60 M(+90.6%) | -$9.50 M(+7.4%) |
| Sept 2020 | - | -$1.89 M(-13.2%) | -$8.84 M(-1.3%) |
| June 2020 | - | -$2.17 M(+18.0%) | -$8.96 M(+12.1%) |
| Mar 2020 | - | -$1.84 M(-37.4%) | -$7.99 M(-5.0%) |
| Dec 2019 | -$8.41 M(+62.5%) | -$2.94 M(+47.1%) | -$8.41 M(+4.2%) |
| Sept 2019 | - | -$2.00 M(+65.6%) | -$8.08 M(+13.0%) |
| June 2019 | - | -$1.21 M(-46.6%) | -$7.15 M(+10.9%) |
| Mar 2019 | - | -$2.26 M(-13.1%) | -$6.45 M(+24.9%) |
| Dec 2018 | -$5.18 M(+148.0%) | -$2.60 M(+142.6%) | -$5.16 M(-882.1%) |
| Sept 2018 | - | -$1.07 M(+112.3%) | $660.00 K(+0.6%) |
| June 2018 | - | -$506.00 K(-48.2%) | $656.00 K(-252.6%) |
| Mar 2018 | - | -$977.00 K(-130.4%) | -$430.00 K(-79.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | -$2.09 M(-86.8%) | $3.22 M(-398.4%) | -$2.09 M(-75.0%) |
| Sept 2017 | - | -$1.08 M(-32.3%) | -$8.36 M(-29.5%) |
| June 2017 | - | -$1.59 M(-39.6%) | -$11.85 M(-15.2%) |
| Mar 2017 | - | -$2.63 M(-13.7%) | -$13.98 M(-11.7%) |
| Dec 2016 | -$15.83 M(+2.4%) | -$3.06 M(-33.2%) | -$15.83 M(-10.1%) |
| Sept 2016 | - | -$4.57 M(+23.1%) | -$17.60 M(+6.0%) |
| June 2016 | - | -$3.71 M(-17.2%) | -$16.61 M(-0.1%) |
| Mar 2016 | - | -$4.49 M(-7.0%) | -$16.63 M(+7.6%) |
| Dec 2015 | -$15.46 M(+118.5%) | -$4.83 M(+34.7%) | -$15.46 M(+11.8%) |
| Sept 2015 | - | -$3.58 M(-4.1%) | -$13.83 M(+11.8%) |
| June 2015 | - | -$3.73 M(+12.7%) | -$12.37 M(+26.9%) |
| Mar 2015 | - | -$3.31 M(+3.8%) | -$9.75 M(+37.8%) |
| Dec 2014 | -$7.08 M(+519.0%) | -$3.19 M(+50.1%) | -$7.07 M(+51.9%) |
| Sept 2014 | - | -$2.13 M(+91.5%) | -$4.66 M(+71.1%) |
| June 2014 | - | -$1.11 M(+73.6%) | -$2.72 M(+56.0%) |
| Mar 2014 | - | -$640.00 K(-17.8%) | -$1.75 M(+57.9%) |
| Dec 2013 | -$1.14 M(+399.1%) | -$779.00 K(+305.7%) | -$1.10 M(+239.0%) |
| Sept 2013 | - | -$192.00 K(+43.3%) | -$326.00 K(+143.3%) |
| June 2013 | - | -$134.00 K | -$134.00 K |
| Dec 2012 | -$229.00 K(-71.0%) | - | - |
| Dec 2002 | -$791.00 K(-50.1%) | - | - |
| Dec 2001 | -$1.59 M(+27.0%) | - | - |
| Dec 2000 | -$1.25 M(+102.1%) | - | - |
| Dec 1999 | -$618.00 K(-58.4%) | - | - |
| Dec 1998 | -$1.49 M(-28.6%) | - | - |
| Dec 1997 | -$2.08 M | - | - |
FAQ
- What is Enlivex Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual EBITDA year-on-year change?
- What is Enlivex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly EBITDA year-on-year change?
- What is Enlivex Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM EBITDA year-on-year change?
What is Enlivex Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ENLV is -$24.32 M
What is the all time high annual EBITDA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$229.00 K
What is Enlivex Therapeutics annual EBITDA year-on-year change?
Over the past year, ENLV annual earnings before interest, taxes, depreciation & amortization has changed by +$704.00 K (+2.81%)
What is Enlivex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ENLV is -$2.83 M
What is the all time high quarterly EBITDA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $3.22 M
What is Enlivex Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ENLV quarterly earnings before interest, taxes, depreciation & amortization has changed by +$2.59 M (+47.80%)
What is Enlivex Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ENLV is -$17.89 M
What is the all time high TTM EBITDA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $660.00 K
What is Enlivex Therapeutics TTM EBITDA year-on-year change?
Over the past year, ENLV TTM earnings before interest, taxes, depreciation & amortization has changed by +$8.16 M (+31.31%)